Evidence map›Paper›PMID 26888921›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2016

Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy.

Nadia Mazzaro, Erica Barini, Maria Grazia Spillantini, Michel Goedert, Paolo Medini, Laura Gasparini

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 97 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Neuronal KActa pharmacologica Sinica · 2024
    Review
  7. Review
  8. Article
  9. Review
  10. Differential contribution of TrkB and p75Frontiers in molecular neuroscience · 2023
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Nadia MazzaroDepartment of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, 16163 Genova, Italy.
Erica BariniDepartment of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, 16163 Genova, Italy.
Maria Grazia SpillantiniCambridge Centre for Brain Repair, University of Cambridge, Cambridge CB2 2PY, United Kingdom, and.
Michel GoedertMedical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom.
Paolo MediniDepartment of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, 16163 Genova, Italy.
Laura GaspariniDepartment of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, 16163 Genova, Italy, laura.gasparini@abbvie.com.ORCID http://orcid.org/0000-0003-3894-9898
Italian Institute of Technology · ITMRC Laboratory of Molecular Biology · GBUniversity of Cambridge · GB

Funding

Medical Research Council MC_U105184291
6 · The paper itself

Abstract

Tauopathies are neurodegenerative diseases characterized by intraneuronal inclusions of hyperphosphorylated tau protein and abnormal expression of brain-derived neurotrophic factor (BDNF), a key modulator of neuronal survival and function. The severity of both these pathological hallmarks correlate with the degree of cognitive impairment in patients. However, how tau pathology specifically modifies BDNF signaling and affects neuronal function during early prodromal stages of tauopathy remains unclear. Here, we report that the mild tauopathy developing in retinal ganglion cells (RGCs) of the P301S tau transgenic (P301S) mouse induces functional retinal changes by disrupting BDNF signaling via the TrkB receptor. In adult P301S mice, the physiological visual response of RGCs to pattern light stimuli and retinal acuity decline significantly. As a consequence, the activity-dependent secretion of BDNF in the vitreous is impaired in P301S mice. Further, in P301S retinas, TrkB receptors are selectively upregulated, but uncoupled from downstream extracellular signal-regulated kinase (ERK) 1/2 signaling. We also show that the impairment of TrkB signaling is triggered by tau pathology and mediates the tau-induced dysfunction of visual response. Overall our results identify a neurotrophin-mediated mechanism by which tau induces neuronal dysfunction during prodromal stages of tauopathy and define tau-driven pathophysiological changes of potential value to support early diagnosis and informed therapeutic decisions. SIGNIFICANCE STATEMENT: This work highlights the potential molecular mechanisms by which initial tauopathy induces neuronal dysfunction. Combining clinically used electrophysiological techniques (i.e., electroretinography) and molecular analyses, this work shows that in a relevant model of early tauopathy, the retina of the P301S mutant human tau transgenic mouse, mild tau pathology results in functional changes of neuronal activity, likely due to selective impairment of brain-derived neurotrophic factor signaling via its receptor, TrkB. These findings may have important translational implications for early diagnosis in a subset of Alzheimer's disease patients with early visual symptoms and emphasize the need to clarify the pathophysiological changes associated with distinct tauopathy stages to support informed therapeutic decisions and guide drug discovery.

Indexed as

tau ProteinsAnimalsBrain-Derived Neurotrophic FactorElectroretinographyMAP Kinase Signaling SystemMiceMice, Inbred C57BLMice, TransgenicNerve Growth FactorsPhotic StimulationReceptor, trkBRetinal Ganglion CellsTauopathiesTissue ExtractsVision, OcularVisual AcuityBrain-Derived Neurotrophic FactorNerve Growth FactorsReceptor, trkBtau ProteinsTissue ExtractsBDNFelectroretinographyneuronal dysfunctionretinal ganglion cellstau proteinTrkB receptor

Identifiers

PMID26888921
PMCPMC4756149
OpenAlexW2283812877

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.